About this trial
The University of Antwerp developed a device (Femiset) to alleviate defecation difficulties in women suffering from Descending Perineum Syndrome (DPS). The device allows the patient to apply counterpressure to the site of descent (perineal body) during defecation, thereby correcting the excessive descent of the perineum so that the increase in abdominal pressure during the (attempted) defecation results in the evacuation of the stool from the rectum and anus, rather than a further downward pressure on the already descended perineum.
The aim of the clinical study is to validate the efficacy (improvement in defecation) and safety of Femiset as compared to the standard of care of no support to the perineum through a clinical study on 20 patients. The population to be studied consists of adult women suffering from DPS with symptoms of obstructive defecation. Patients will use the device in their home environment for four weeks. The improvement in defecation as perceived by the patient will be assessed with the Patient Global Impression of Change (PGIC) scale. Secondarily, their ODS symptoms will be assessed prior to the test period and at the end of the test period using the Modified Longo Score for ODS. These scores will be compared to determine if there has been an improvement in ODS symptoms. The safety of the device will be validated based on monitoring the incidence of adverse events during the test period. The study will also explore the usability of the device and how it compares to manual perineal support. The results of the study will determine the product's viability.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Woman at birth
Adult (aged 18+)
ODS complaints
MRI has been performed within the past three years and a perineal descent of >4cm on MRI (M-Line) is present
Disqualifiers
Scoring less than 7/24 on the modified Longo Score for ODS
Need for vaginal splinting
Severe perineal malformations
Recent perineal surgery (<6 weeks)
Trial design
Single group
Treatments tested in this trial
Use device in home environment
DevicePatients will use the device in their home environment for four weeks.
Treatment groups
Trial outcomes
Primary outcomes
Efficacy - improvement in defecation
PGIC Scale
Safety - incidence of adverse events
Absence of any adverse events classified with a device-related causality level higher than "not related", as per MDCG 2020-10/1, and assessed by the PI as severe.
Secondary outcomes
Efficacy - improvement in ODS symptoms
Modified Longo Score for ODS
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: